Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, DENTSPLY Sirona Inc’s stock clocked out at $11.02, down -12.68% from its previous closing price of $12.62. In other words, the price has decreased by -$12.68 from its previous closing price. On the day, 10.23 million shares were traded. XRAY stock price reached its highest trading level at $11.36 during the session, while it also had its lowest trading level at $10.7.
Ratios:
To gain a deeper understanding of XRAY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.12 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.93. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.69. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.18.
On February 14, 2025, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.Wells Fargo initiated its Equal Weight rating on February 14, 2025, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when LUCIER GREGORY T bought 15,142 shares for $16.51 per share. The transaction valued at 249,994 led to the insider holds 81,971 shares of the business.
Coleman Glenn bought 15,759 shares of XRAY for $311,240 on Jan 27 ’25. On Nov 18 ’24, another insider, LUCIER GREGORY T, who serves as the Director of the company, bought 5,000 shares for $18.37 each. As a result, the insider paid 91,850 and bolstered with 71,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XRAY now has a Market Capitalization of 2198312192 and an Enterprise Value of 4668486144. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.60 while its Price-to-Book (P/B) ratio in mrq is 1.12. Its current Enterprise Value per Revenue stands at 1.272 whereas that against EBITDA is 7.458.
Stock Price History:
The Beta on a monthly basis for XRAY is 1.00, which has changed by -0.29339308 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, XRAY has reached a high of $24.86, while it has fallen to a 52-week low of $11.69. The 50-Day Moving Average of the stock is -15.50%, while the 200-Day Moving Average is calculated to be -26.96%.
Shares Statistics:
It appears that XRAY traded 3.30M shares on average per day over the past three months and 2585610 shares per day over the past ten days. A total of 199.30M shares are outstanding, with a floating share count of 198.24M. Insiders hold about 0.63% of the company’s shares, while institutions hold 102.20% stake in the company. Shares short for XRAY as of 1760486400 were 8961408 with a Short Ratio of 2.72, compared to 1757894400 on 8862044. Therefore, it implies a Short% of Shares Outstanding of 8961408 and a Short% of Float of 5.0100001999999995.
Earnings Estimates
The dynamic stock of DENTSPLY Sirona Inc (XRAY) is currently attracting attention from 14.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.47, with high estimates of $0.55 and low estimates of $0.45.
Analysts are recommending an EPS of between $1.94 and $1.6 for the fiscal current year, implying an average EPS of $1.83. EPS for the following year is $1.92, with 15.0 analysts recommending between $2.3 and $1.15.
Revenue Estimates
In. The current quarter, 14 analysts expect revenue to total $931.08M. It ranges from a high estimate of $975M to a low estimate of $906M. As of. The current estimate, DENTSPLY Sirona Inc’s year-ago sales were $905MFor the next quarter, 14 analysts are estimating revenue of $908.26M. There is a high estimate of $939.25M for the next quarter, whereas the lowest estimate is $889M.
A total of 16 analysts have provided revenue estimates for XRAY’s current fiscal year. The highest revenue estimate was $3.68B, while the lowest revenue estimate was $3.62B, resulting in an average revenue estimate of $3.65B. In the same quarter a year ago, actual revenue was $3.79BBased on 16 analysts’ estimates, the company’s revenue will be $3.69B in the next fiscal year. The high estimate is $3.78B and the low estimate is $3.55B.
